ArticleJournal of Alzheimer's disease : JAD2015
Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.
Article in Journal of Alzheimer's disease : JAD, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 5 syntheses or guidelines pooled it, 195 citations in OpenAlex.
- Intestinal Flora Balance Therapy Based on Probiotic Support Improves Cognitive Function and Symptoms in Patients with Alzheimer's Disease: A Systematic Review and Meta-analysis.BioMed research international · 2022Pooled it
- Cross-sectional associations of amyloid burden with semantic cognition in older adults without dementia: A systematic review and meta-analysis.Mechanisms of ageing and development · 2020Pooled it
- Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis.Alzheimer's research & therapy · 2019Pooled it
- Diagnostic Accuracy of Memory Measures in Alzheimer's Dementia and Mild Cognitive Impairment: a Systematic Review and Meta-Analysis.Neuropsychology review · 2017Pooled it
- Detectable Neuropsychological Differences in Early Preclinical Alzheimer's Disease: A Meta-Analysis.Neuropsychology review · 2017Pooled it
- Advancing Alzheimer's disease research in China: insights, innovations, and future directions from the chinese preclinical Alzheimer's disease study (CPAS).Molecular psychiatry · 2026Review
- Validity of the Inventory of Depressive Symptomatology Self-Report (IDS-SR) in Older Adults With Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI).BMC psychology · 2026Article
- Digital neuropsychological assessment-part 1: Defining mild cognitive impairment subtypes.Journal of Alzheimer's disease : JAD · 2026Article
- Associations between the logical memory test story recall metrics and plasma biomarkers for Alzheimer's disease in individuals free of dementia.The Clinical neuropsychologist · 2026Article
- Longitudinal Associations of Multimodal Core 1 Alzheimer Disease Biomarkers With Cognition in Aging and Preclinical Alzheimer Disease.Neurology · 2025Observational
- Beyond Alzheimer's disease-translating biomarker insights across CNS diseases.Science translational medicine · 2025Review
- Precision neurocognition: An emerging diagnostic paradigm leveraging digital cognitive assessment technology.Journal of Alzheimer's disease : JAD · 2025Review
- Early identification of cognitive impairment in older adults from Advanced Activities of Daily Living (AADL): A scoping review.Public health · 2025Article
- Metagenomic analysis characterizes stage-specific gut microbiota in Alzheimer's disease.Molecular psychiatry · 2025Article
- Development and Preliminary Validation of Standardized Regression-Based Change Scores as Measures of Transitional Cognitive Decline.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2025Article
- Reliability and validity analysis of the Chinese version of the Quick Dementia Rating System (QDRS).BMC geriatrics · 2025Article
- Sarcopenia index is associated with Alzheimer's disease, mild cognitive impairment and their mortality in Chinese adults aged 65 and older.BMC public health · 2025Article
- Association of objective subtle cognitive difficulties with amyloid-β and tau deposition compared to subjective cognitive decline.European journal of nuclear medicine and molecular imaging · 2025Article
- Tau PET positivity predicts clinically relevant cognitive decline driven by Alzheimer's disease compared to comorbid cases; proof of concept in the ADNI study.Molecular psychiatry · 2025Article
- Mood Symptoms are Associated With Cognitive Status, Brain Amyloid-Beta Deposition, and Plasma Biomarkers.Depression and anxiety · 2025Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The NIA-AA criteria for "preclinical" Alzheimer's disease (AD) propose a staging method in which AD biomarkers follow an invariable temporal sequence in accordance with the amyloid cascade hypothesis. However, recent findings do not align with the proposed temporal sequence and "subtle cognitive decline," which has not been definitively operationalized, may occur earlier than suggested in preclinical AD. We aimed to define "subtle cognitive decline" using sensitive and reliable neuropsychological tests, and to examine the number and sequence of biomarker abnormalities in the Alzheimer's Disease Neuroimaging Initiative (ADNI). 570 cognitively normal ADNI participants were classified based on NIA-AA criteria and separately based on the number of abnormal biomarkers/cognitive markers associated with preclinical AD that each individual possessed. Results revealed that neurodegeneration alone was 2.5 times more common than amyloidosis alone at baseline. For those who demonstrated only one abnormal biomarker at baseline and later progressed to mild cognitive impairment/AD, neurodegeneration alone was most common, followed by amyloidosis alone or subtle cognitive decline alone, which were equally common. Findings suggest that most individuals do not follow the temporal order proposed by NIA-AA criteria. We provide an operational definition of subtle cognitive decline that captures both cognitive and functional decline. Additionally, we offer a new approach for staging preclinical AD based on number of abnormal biomarkers, without regard to their temporal order of occurrence. This method of characterizing preclinical AD is more parsimonious than the NIA-AA staging system and does not presume that all patients follow a singular invariant expression of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.